title: Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
abstract: Although highly active in hairy cell leukemia (HCL), interferons (IFN) are not curative in this disease; current data indicate that prolonged IFN therapy will be necessary to control disease in the majority of patients. We previously observed acquired IFN resistance in association with neutralizing IFN-alpha 2a antibodies in small numbers of patients with HCL. This finding suggests that the requisite long-term therapy may be compromised if there is an increasing incidence over time of neutralizing antibodies. We performed a follow-up study of IFN antibodies in our patients receiving continuous IFN therapy. All 16 patients who were previously antibody negative remained so. Surprisingly, all nine patients who previously had non-neutralizing IFN antibodies became antibody negative after a median of 14.5 months. Moreover, 3 of 10 patients who had neutralizing antibodies became antibody negative and five had only non-neutralizing antibodies a median of 10 months from the time neutralizing antibody had first been detected. Only two patients had persisting neutralizing antibodies. Inhibition of neopterin synthesis, inhibition of generation of 2', 5' oligoadenylate synthetase activity, and inability to detect IFN in serum after subcutaneous injection of IFN-alpha 2a was observed only in the one patient tested with neutralizing IFN antibodies confirming that these antibodies have functional significance in vivo. We conclude that, although neutralizing IFN antibodies inhibit the effectiveness of IFN in vivo, these antibodies are produced only transiently during long-term therapy. The long-term effectiveness of this drug will not likely be affected in most patients by neutralizing antibody.
authors.affiliation: Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21701.
authors.forename: R G
authors.initials: RG
authors.lastname: Steis
authors.forename: J W
authors.initials: JW
authors.lastname: Smith
authors.forename: W J
authors.initials: WJ
authors.lastname: Urba
authors.forename: D J
authors.initials: DJ
authors.lastname: Venzon
authors.forename: D L
authors.initials: DL
authors.lastname: Longo
authors.forename: R
authors.initials: R
authors.lastname: Barney
authors.forename: L M
authors.initials: LM
authors.lastname: Evans
authors.forename: L M
authors.initials: LM
authors.lastname: Itri
authors.forename: C H
authors.initials: CH
authors.lastname: Ewel
mesh_terms: D000906:Antibodies / Q000032:analysis*; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D001831:Body Temperature; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D007372:Interferons / Q000097:blood / Q000276:immunology*; D007700:Kinetics; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000276:immunology; D019798:Neopterin; D009500:Neutralization Tests; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D000906:Antibodies; D007370:Interferon Type I; D011994:Recombinant Proteins; D001708:Biopterins; D019798:Neopterin; D007372:Interferons